Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Multigene Assay Predicts Cancer Patient's Survival

By Labmedica International staff writers
Posted on 19 Aug 2014
Image: Histopathology of clear cell renal cell carcinoma (Photo courtesy of Nephron).
Image: Histopathology of clear cell renal cell carcinoma (Photo courtesy of Nephron).
Patients with clear cell renal cell carcinoma (ccRCC) have divergent survival outcomes and therapeutic responses, which may be determined by underlying molecular diversity.

A practical molecular assay has been developed that can identify subtypes with differential prognosis and response to targeted therapy and predict treatment and survival outcomes in kidney cancer patients.

Scientists at the Institute of Bioengineering and Nanotechnology (Republic of Singapore) and their colleagues conducted a retrospective study with a cohort of 279 ccRCC patients who underwent surgery at Singapore General Hospital (Republic of Singapore) between 1999 and 2012. They developed a practical expression-based assay with utility in formalin-fixed paraffin-embedded (FFPE) material that assigns biologic subtypes of ccRCC, characterized by differential prognosis and treatment response.

Ribonucleic acid (RNA) was extracted from a set of 55 FFPE samples (SGH-55) and processed for whole-genome expression analysis by Whole Genome (WG)-DASL (Illumina; San Diego, CA, USA). Quantitative polymerase chain reaction (qPCR) assays were designed for measuring expression in FFPE tissue; expression data for potential prognostic and normalization genes for SGH-55 were collected. A model assigning prognostic subtype was developed based on the combination of qPCR expression values of eight genes: chemokine (C-X-C motif) ligand 5 (CXCL5), ephrin A5 (EFNA5), endomucin (EMCN), laminin beta3 (LAMB3), plasminogen (PLG), preferentially expressed antigen in melanoma (PRAME), retinoic acid receptor responder (tazarotene induced) 1 (RARRES1), and solute carrier family 6 (neutral amino acid transporter), member 19 (SLC6A19).

Min-Han Tan, MBBS, PhD, the senior author of the study, said, “Our diagnostic assay successfully classified ccRCC into groups that correlated to different survival and treatment outcomes. This allows patients and doctors to make more educated choices in their treatment options. Outcomes can be very different. Some patients can be observed for years on end, some benefit from immediate treatment including surgery or targeted therapy, and for some patients, treatment can be futile. Experience is required in making the right judgment for patients. We hope our assay will play a role in helping that judgment.” The study was published on July 10, 2014, in the journal European Urology.

Related Links:

Institute of Bioengineering and Nanotechnology
Singapore General Hospital 
Illumina



77 ELEKTRONIKA
DRG International
DiagCor Bioscience
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: The gel zymography separation of matrix metalloproteinases (MMPs) on a 7.5% polyacrylamide gel (Photo courtesy of the Italian National Research Council).

Quantitative Gel Zymography Reappraised for Matrix Metalloproteinases

A reappraisal of quantitative gel zymography technique for matrix metalloproteinases (MMPs) in human plasma has been used for comparison with commercially available enzyme-linked immunosorbent assay (ELISA).... Read more

Industry News

view channel

French-German Cooperation to Improve Personalized Cancer Care

A leading French oncology center will be collaborating with a German manufacturer of molecular diagnostic tests to develop new approaches to personalized cancer care. The Gustave Roussy Cancer Campus (Paris, France), a medical center with 2,600 health professionals dedicated to cancer diagnosis and treatment that devotes... Read more
 

Events

06 Nov 2014 - 08 Nov 2014
12 Nov 2014 - 15 Nov 2014
Copyright © 2000-2014 Globetech Media. All rights reserved.